Get Premium Data for Cyber Monday: Up to 55% Off InvestingProCLAIM SALE

BioArctic AB (BIOAb)

Stockholm
Currency in SEK
183.3000
-2.6000(-1.40%)
Closed
BIOAb Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
Fair Value
Day's Range
181.1000186.4000
52 wk Range
137.7000288.4000
Key Statistics
Edit
Prev. Close
185.9
Open
185.1
Day's Range
181.1-186.4
52 wk Range
137.7-288.4
Volume
126.57K
Average Volume (3m)
289.53K
1-Year Change
-21.67%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIOAb Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
322.0000
Upside
+75.6683%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market
Show more

BioArctic AB Company Profile

BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer’s disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer’s disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer’s disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson’s disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Compare BIOAb to Peers and Sector

Metrics to compare
BIOAb
Peers
Sector
Relationship
P/E Ratio
−69.6x−2.1x−0.7x
PEG Ratio
0.36−0.020.00
Price/Book
17.6x2.3x2.6x
Price / LTM Sales
96.9x6.7x3.2x
Upside (Analyst Target)
73.5%145.3%46.6%
Fair Value Upside
Unlock27.1%7.4%Unlock

Analysts' Recommendations

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 322.0000

(+75.67% Upside)

People Also Watch

64.5000
PRY
+0.16%
359.20
BONEX
+0.96%
785.5
NOVOb
+1.88%
37.28
HTRO
+1.86%
547.00
CAMX
+0.09%

FAQ

What Is the BioArctic (BIOAb) Stock Price Today?

The BioArctic stock price today is 183.30

What Stock Exchange Does BioArctic Trade On?

BioArctic is listed and trades on the Stockholm stock exchange.

What Is the Stock Symbol for BioArctic?

The stock symbol for BioArctic is "BIOAb."

What Is the BioArctic Market Cap?

As of today, BioArctic market cap is 16.20B.

What is BioArctic Earnings Per Share?

The BioArctic EPS is -2.64.

What Is the Next BioArctic Earnings Date?

BioArctic will release its next earnings report on Feb 12, 2025.

From a Technical Analysis Perspective, Is BIOAb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.